Return to homepagePandemic Pact

SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS

  • Funded by Biomedical Advanced Research and Development Authority (BARDA)
  • Total publications:0 publications

Grant number: 75A50120C00096

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $48,927,887

  • Funder

    Biomedical Advanced Research and Development Authority (BARDA)

  • Research Location

    United States of America

  • Lead Research Institution

    MAYO CLINIC

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS